美国和加拿大孕期仅使用大麻二酚产品的情况：国际大麻政策研究的结果
Cannabidiol-Only Product Use in Pregnancy in the United States and Canada: Findings From the International Cannabis Policy Study.
作者信息
Bhatia Devika, Battula Sharonya, Mikulich-Gilbertson Susan, Sakai Joseph, Hammond David
机构信息
Department of Psychiatry, Colorado School of Medicine, University of Colorado Anschutz Medical Campus, Aurora CO; and the School of Public Health and Health Systems, University of Waterloo, Waterloo, Ontario, Canada.
出版信息
Obstet Gynecol. 2024 Aug 1;144(2):156-159. doi: 10.1097/AOG.0000000000005603. Epub 2024 May 9.
This study aimed to characterize pregnant individuals' use of cannabidiol (CBD). Data are from the International Cannabis Policy Study (2019-2021), a repeated cross-sectional survey of individuals aged 16-65 years in the United States and Canada (N=66,457 women, including 1,096 pregnant women). The primary analysis compared pregnant and nonpregnant women's CBD-only product use patterns and reasons for use. The prevalence of CBD-only use in pregnant women was 20.4% compared with 11.3% among nonpregnant women, P <.001. Reasons for CBD use among pregnant women included anxiety (58.4%), depression (40.3%), posttraumatic stress disorder (32.1%); pain (52.3%), headache (35.6%), and nausea or vomiting (31.9%). Thus, CBD-only product use was prevalent in this large sample, with one in five pregnant women reporting use. Characterization of prenatal CBD use is an important first step to exploring potential risks to exposed offspring.
本研究旨在描述孕妇使用大麻二酚（CBD）的情况。数据来自国际大麻政策研究（2019 - 2021年），这是一项对美国和加拿大16 - 65岁个体进行的重复横断面调查（N = 66,457名女性，包括1,096名孕妇）。主要分析比较了孕妇和非孕妇仅使用CBD产品的使用模式及使用原因。孕妇中仅使用CBD的比例为20.4%，而非孕妇为11.3%，P <.001。孕妇使用CBD的原因包括焦虑（58.4%）、抑郁（40.3%）、创伤后应激障碍（32.1%）；疼痛（52.3%）、头痛（35.6%）以及恶心或呕吐（31.9%）。因此，在这个大样本中，仅使用CBD产品的情况很普遍，五分之一的孕妇报告使用过。描述产前CBD的使用情况是探索对暴露后代潜在风险的重要第一步。
Zotero 插件